No Data
FBI Firearm Background Checks Track Higher Ahead of the U.S. Election
Piper Sandler Maintains Olin(OLN.US) With Buy Rating, Cuts Target Price to $51
Olin Is Maintained at Market Perform by BMO Capital
Olin Biology (688319.SH): The proposed additional fundraising will not exceed 0.3 billion yuan.
On October 29, Gelonhui announced that Olin Biotech (688319.SH) disclosed that the total amount of funds raised by the company in this issuance of stocks shall not exceed 175.2929 million yuan (including this amount), not more than 0.3 billion yuan and not more than 20% of the net assets at the end of the most recent year. The net proceeds from the funds raised after deducting the relevant issuance expenses are intended to be invested in the following project: the technical renovation project of the vaccine R&D production base.
Morgan Stanley Maintains Olin(OLN.US) With Sell Rating, Maintains Target Price $41
Express News | Olin Corp : BMO Cuts Target Price to $47 From $50
No Data
No Data
